This post was originally published on this site Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP) Registry, allowing people with multiple myeloma to securely submit their health data to MMRF CureCloud, the foundation’s data repository. This is the first data repository to gather people’s longitudinal…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
FDA Grants Breakthrough Therapy Status to Ofev for Sarcoidosis, Other ILDs
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Ofev (nintedanib) for the treatment of patients with sarcoidosis and other types of progressive fibrosing interstitial lung diseases (ILDs). The breakthrough designation is given to medications that provide significant advantages over currently available…
Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows
This post was originally published on this site Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy alone, a Phase 3 trial shows. The research, “Clinical Outcomes by Chemotherapy Regimen in Patients with RS…
Pomalyst Combo Appears Effective in Multiple Myeloma Patients Refractory to Revlimid, Trial Reports
This post was originally published on this site Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst (pomalidomide) and low-dose dexamethasone, results of a Phase 2 clinical trial in a first patient group suggest. An overall response “was achieved by 32·1% of…
$35M Gift from Benioffs to Support Prostate Cancer Research Initiative at UCSF
This post was originally published on this site A $35 million gift from Marc and Lynne Benioff will support a new initiative at the University of California, San Francisco (UCSF) aimed at finding personalized treatments for prostate cancer. “With this gift, we are honoring the memory of Marc’s father and all of those who have…
Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment
This post was originally published on this site The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, has announced. This is in addition to a prior fast track designation granted in 2017 for the…
Zejula Granted FDA’s Breakthrough Therapy Status for Treating Metastatic Castration-resistant Prostate Cancer
This post was originally published on this site The oral ovarian cancer treatment Zejula (niraparib) has been given Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who carry BRCA mutations and have been previously treated with certain therapies, namely taxane chemotherapy and androgen-receptor…
Navicixizumab Earns FDA Fast Track Designation for Heavily Pretreated Ovarian Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast track designation is given to investigational compounds that show considerable potential in treating serious conditions for which available…
Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma
This post was originally published on this site IASO Biotherapeutics and Innovent Biologics are preparing the launch of a Phase 1b/2 clinical trial in China to evaluate the companies’ novel CAR T-cell product, CT103A, in people with relapsed or refractory multiple myeloma. The announcement comes after the therapy was granted Investigational New Drug status by…
Keytruda Approved in China as First-Line Lung Cancer Treatment
This post was originally published on this site The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) announced. The approval covers patients who have tumors with at least 1% of cells producing the PD-L1 protein,…
Terranea Resort Turns Pink for National Breast Cancer Awareness Month
This post was originally published on this site In observance of National Breast Cancer Awareness Month, the Los Angeles oceanfront resort Terranea will again “turn pink” to benefit breast cancer organizations. Throughout October, Terranea will — for the fourth year — reprise its “Terranea Turns Pink” initiative, which donates a portion of proceeds from golf…
Consolidation Radiotherapy Important After Treatment for Early Hodgkin’s Lymphoma, Clinical Study Shows
This post was originally published on this site Radiotherapy following chemotherapy reduces the risk of cancer progression in people with early-stage favorable Hodgkin’s lymphoma, regardless of an individual’s response to chemotherapy, results of a Phase 3 study show. These findings support the importance of consolidation radiotherapy — which appears to prevent potential cancer relapse or…